Cover Image

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

Thalidomide (Thal) is a drug with anti-angiogenic properties. To explore whether the effect of Thal on angiogenesis is associated with a reduction of angiogenic cytokine levels in progressive multiple myeloma (MM), plasma levels of basic fibroblast growth factor, vascular endothelial growth factor,...

Full description

Saved in:
Bibliographic Details
Main Authors: Neben, Kai (Author) , Möhler, Thomas (Author) , Krämer, Alwin (Author) , Benner, Axel (Author) , Egerer, Gerlinde (Author) , Ho, Anthony Dick (Author) , Goldschmidt, Hartmut (Author)
Format: Article (Journal)
Language:English
Published: 20 December 2001
In: British journal of haematology
Year: 2001, Volume: 115, Issue: 3, Pages: 605-608
ISSN:1365-2141
DOI:10.1046/j.1365-2141.2001.03142.x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1046/j.1365-2141.2001.03142.x
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2141.2001.03142.x
Get full text
Author Notes:Kai Neben, Thomas Moehler, Alwin Kraemer, Axel Benner, Gerlinde Egerer, Anthony D. Ho and Hartmut Goldschmidt
Description
Summary:Thalidomide (Thal) is a drug with anti-angiogenic properties. To explore whether the effect of Thal on angiogenesis is associated with a reduction of angiogenic cytokine levels in progressive multiple myeloma (MM), plasma levels of basic fibroblast growth factor, vascular endothelial growth factor, interleukin 6, tumour necrosis factor-α and hepatocyte growth factor (HGF) were measured in 51 patients at 0, 3 and 6 months of Thal therapy. After 6 months of treatment, 26 patients were considered to be responsive to Thal therapy, including 17 minimal responses, eight partial responses and one complete response. Only HGF (decreasing, P = 0·02) in the group of responsive patients showed a statistically significant change over a period of 6 months. Because HGF levels are known to correlate to MM tumour burden, we conclude that the mechanism of action of Thal in MM is not caused by a specific inhibition of angiogenic cytokine secretion.
Item Description:Gesehen am 14.12.2021
Physical Description:Online Resource
ISSN:1365-2141
DOI:10.1046/j.1365-2141.2001.03142.x

Similar Items